CT 7001

Drug Profile

CT 7001

Alternative Names: CT7001; ICEC0942

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Imperial College of Science, Technology and Medicine
  • Developer Carrick Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Preclinical Acute myeloid leukaemia; Breast cancer; Small cell lung cancer

Most Recent Events

  • 04 Dec 2017 Pharmacodynamics data from a preclinical study in Acute myeloid leukaemia released by Carrick Therapeutics
  • 30 Nov 2017 Phase-I clinical trials in Cancer in Ireland (PO)
  • 30 Nov 2017 Preclinical trials in Acute myeloid leukaemia in Ireland (PO) before November 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top